Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 8 sources
Doses in NATiV3: 800 mg or 1200 mg once daily
| Arm | Registered regimen |
|---|---|
| Lanifibranor 800 mg/day | “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food” |
| Lanifibranor 1200 mg/day | “3 Lanifibranor tablets 400mg with food” |
| Placebo | “3 Placebo to match tablets with food” |
Company description of the dosing regimen
Doses of 800 mg and 1200 mg once daily for 24 weeks and the biomarker basis for their selection
Single-center phase 2 study in type 2 diabetes and MASLD: 800 mg
Dose modification and treatment interruption in the trials
Commercial dose and dose adjustment for special populations
No evidence found.